Table IV.
Drugs for Cytokine Therapy
| Cytokine ligand | Receptor family | Type of cancer | Clinical trial stage | References/ Trial identifier |
|---|---|---|---|---|
| IL-2 | Type I | Metastatic Renal Cell Carcinoma, Metastatic melanoma | FDA (1992) | [120] |
| IFN-α | Type II | Hairy Cell Leukemia, Malignant Melanoma, Follicular Lymphoma, AIDS-Related Kaposi’s Sarcoma | FDA (1986) | [128] |
| IFN-γ | Type II | Metastatic renal cell carcinoma | Phase III | [129] |
| IL-7 | Type I | Refractory cancer | Phase I | NCT00062049 |
| Metastatic Melanoma | Phase I | [130] | ||
| IL-6 | Type I | Advanced multiple myeloma | Phase I | [131] |
| IL-12 | Type I | Metastatic renal cell carcinoma | Phase I | [132] |
| GM-CSF | Type I | Metastatic melanoma | Phase I | [133] |